Healios KK Advances Global Phase 3 Trial for ARDS Treatment

Healios KK ( (JP:4593) ) has issued an update.

Healios KK has completed regulatory consultations in Japan for its investigational ARDS treatment and is preparing for a global Phase 3 trial, REVIVE-ARDS, primarily in the United States. This agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) to include Japanese patients is expected to accelerate the trial’s progress, potentially enhancing the company’s position in the global biotechnology market and offering new hope for ARDS patients worldwide.

More about Healios KK

Healios KK operates in the biotechnology industry, focusing on developing innovative treatments for critical conditions such as Acute Respiratory Distress Syndrome (ARDS). The company is engaged in creating therapies that address unmet medical needs, particularly in areas where current treatment options are limited.

YTD Price Performance: 65.54%

Average Trading Volume: 3,282,925

Technical Sentiment Signal: Sell

Current Market Cap: Yen29.73B

See more data about 4593 stock on TipRanks’ Stock Analysis page.